High-dose lymphoablative therapy (HDLT) with or without stem-cell rescue for treatment of severe autoimmune diseases

BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

The BlueCross BlueShield Association Technology Evaluation Center website (www.bcbs.com/tec) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website.

Citation

Authors' objectives
This Assessment summarizes published evidence from pilot studies and phase I/II trials of high-dose lymphoablative therapy with or without autologous stem-cell rescue for the treatment of severe autoimmune disease to determine the procedures effect on health outcomes.

Project page URL
http://www.bcbs.com/blueresources/tec/contact-tec.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; Immunosuppressive Agents

Language Published
English

Country of organisation
United States

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32003000728

Date bibliographic record published
13/08/2003

Date abstract record published
13/08/2003